Kura Oncology Inc
KURA
NASDAQ
Biotechnology
$10.86
USD
+0.77 (+7.63%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $915.26M
Volume 1.9M
Revenue
$77.22M
TTM
-7.3%
YoY
Gross Margin
99%
TTM
-0.7%
YoY
Net Income
$-296.77M
TTM
-50.5%
YoY
Operating Cash Flow
$-111.76M
TTM
-189.4%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 15.3 | 20.8 | 17.3 | 18.3 | 20.9 |
YoY Growth | — | — | -67.8% | +29.5% | +36.5% |
Cost of Revenue | 0.0 | 0.0 | 0.1 | 0.3 | 0.2 |
Gross Profit | 15.3 | 20.8 | 17.3 | 18.0 | 20.6 |
Selling, General & Administrative | 25.2 | 32.8 | 39.1 | 31.6 | 31.8 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 88.0 | 100.7 | 103.5 | 96.8 | 93.6 |
Operating Income | -72.7 | -80.0 | -86.3 | -78.8 | -73.0 |
EBITDA | -72.4 | -79.8 | -85.9 | -78.5 | -72.6 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 6.5 | 5.9 | 5.3 | 5.5 | 4.7 |
Income Before Income Taxes | -66.1 | -74.1 | -80.9 | -73.3 | -68.3 |
Income Taxes | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 |
Net Income | -66.1 | -74.1 | -81.0 | -73.3 | -68.3 |
Consolidated Net Income / Loss | -66.1 | -74.1 | -81.0 | -73.3 | -68.3 |
Net Income Attributable to Common Shareholders | -66.1 | -74.1 | -81.0 | -73.3 | -68.3 |
Basic EPS | -$0.75 | -$0.85 | -$0.92 | -$0.83 | -$0.77 |
Diluted EPS | -$0.75 | -$0.85 | -$0.92 | -$0.83 | -$0.77 |
Basic Shares Outstanding | 87.6M | 87.6M | 88.1M | 88.6M | 88.9M |
Diluted Shares Outstanding | 87.6M | 87.6M | 88.1M | 88.6M | 88.9M |